mProX™ Human SSTR2 Stable Cell Line

Product Information

Target Protein

SSTR2

Target Family

Somatostatin Family

Target Protein Species

Human

Host Cell Type

HeLa; INS-1; GH3; CHO-K1; HEK293

Target Classification

GPCR Cell Lines

Target Research Area

Cancer Research; CNS Research

Related Diseases

Type C Thymoma; Neuroendocrine Tumor

Gene ID

6752

UniProt ID

P30874

Product Properties

Biosafety Level

Level 1

Activity

Yes

Quantity

10⁶ cells per vial

Applications

Somatostatin (SST) is a cyclic hormone release-inhibiting peptide that has two physiologically similar subforms, SST14 and SST28, and which negatively regulates cell proliferation, the release of numerous hormones, and the suppression of cancer by activating five SST receptors (SSTR1-5) that are specific to it. SSTR2 is primarily responsible for suppressing glucagon secretion. To selectively inhibit the release of particular hormones through various SSTR subtypes with strong receptor subtype selectivity and stability, a number of synthetic SST analogues must be developed. SSTR2 is one of the five SSTRs and exhibits abnormal expression in numerous cancer cells as well as tumor blood vessels. It inhibits cancer progression and promotes cell death. As a result, SSTR2 is a crucial pharmacological target for the treatment of numerous disorders, including cancer, thyrotropinoma, and neuroendocrine tumors (NETs). The customized SSTR2 stable cell line can be used in antibody discovery and development, potential drug candidate screening and signaling pathway researches.

Protocols

Please visit our protocols page.

Customer Reviews

chat Diana

The quality of work, efficiency, and speed was perfect. Nov 16 2022

chat Verified Customer

chat Ahern

I customized a SSTR2 cell line and the products definitely stand out. Mar 01 2023

chat Verified Customer

FAQ

Any questions about our products? Please visit our frequently asked questions page.

Published Data

Fig.1 Microarray analysis of miRNA expression.

1 μmol/L of octreotide was used to incubate INS-1 and GH3 cells. Total RNA was obtained following the specified incubation period, and miR-16-5p levels were then determined by qRT-PCR and adjusted for input RNA using control miRNA (U87) and the 2−ΔΔCt technique.

Ref: Jo, HanHee, et al. "Elevated miR-16-5p induces somatostatin receptor 2 expression in neuroendocrine tumor cells." PloS one 15.10 (2020): e0240107.

Pubmed: 33045023

DOI: 10.1371/journal.pone.0240107

Research Highlights

For children with relapsed neuroblastoma (NB) who do not respond to I-metaiodobenzylguanidine (MIBG) therapy, other radiolabeled, targeted medicines are being researched. Somatostatin receptors (SSTRs), especially SSTR2, which are expressed on NB cells, are the target of (DOTA-Tyr)-octreotate.
Alexander, Natasha, et al. "Prevalence and clinical correlations of somatostatin receptor-2 (SSTR2) expression in neuroblastoma." Journal of pediatric hematology/oncology 41.3 (2019): 222.
Pubmed: 30334904 DOI: 10.1097/MPH.0000000000001326

The Epstein-Barr virus (EBV), which has been demonstrated to upregulate the somatostatin receptor 2 (SSTR2) cell surface receptor, is known to cause infection in areas where NPC is endemic.
Emanuel, Oscar, et al. "SSTR2 in Nasopharyngeal carcinoma: relationship with latent EBV infection and potential as a therapeutic target." Cancers 13.19 (2021): 4944.
Pubmed: 34638429 DOI: 10.3390/cancers13194944